| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:(R)-BI-2852
CAS:2375482-49-6
Purity:97% Package:1mg;5mg;10mg
|
| Company Name: |
SuZhou GoodChemTech Co., Ltd
|
| Tel: |
18136139868; 18136139868 |
| Email: |
jinlun@goodchemtech.cn |
| Products Intro: |
Product Name:(R)-BI-2852
CAS:2375482-49-6
Package:1g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:(R)-BI-2852
CAS:2375482-49-6
Purity:97.78% Package:1mg/RMB 997;5mg/RMB 1890;10mg/RMB 2990
|
1H-Isoindol-1-one, 2,3-dihydro-5-hydroxy-3-[2-[[[[1-[(1-methyl-1H-imidazol-4-yl)methyl]-1H-indol-6-yl]methyl]amino]methyl]-1H-indol-3-yl]-, (3R)- manufacturers
- (R)-BI-2852
-
- $85.00 / 1mg
-
2025-07-16
- CAS:2375482-49-6
- Min. Order:
- Purity: 97.78%
- Supply Ability: 10g
|
| | 1H-Isoindol-1-one, 2,3-dihydro-5-hydroxy-3-[2-[[[[1-[(1-methyl-1H-imidazol-4-yl)methyl]-1H-indol-6-yl]methyl]amino]methyl]-1H-indol-3-yl]-, (3R)- Basic information |
| | 1H-Isoindol-1-one, 2,3-dihydro-5-hydroxy-3-[2-[[[[1-[(1-methyl-1H-imidazol-4-yl)methyl]-1H-indol-6-yl]methyl]amino]methyl]-1H-indol-3-yl]-, (3R)- Chemical Properties |
| Boiling point | 906.5±65.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | form | Solid | | pka | 8.95±0.40(Predicted) | | color | Off-white to light yellow |
| | 1H-Isoindol-1-one, 2,3-dihydro-5-hydroxy-3-[2-[[[[1-[(1-methyl-1H-imidazol-4-yl)methyl]-1H-indol-6-yl]methyl]amino]methyl]-1H-indol-3-yl]-, (3R)- Usage And Synthesis |
| Uses | (R)-BI-2852 is the isomer of BI-2852 (HY-126247), and can be used as an experimental control. BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells. | | References | [1] Dirk Kessler, et al. Drugging all RAS isoforms with one pocket. FUTURE MEDICINAL CHEMISTRY
[2] Kessler D, et al. Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci U S A. 2019 Aug 6; 116(32):15823-15829. DOI:10.1073/pnas.1904529116 |
| | 1H-Isoindol-1-one, 2,3-dihydro-5-hydroxy-3-[2-[[[[1-[(1-methyl-1H-imidazol-4-yl)methyl]-1H-indol-6-yl]methyl]amino]methyl]-1H-indol-3-yl]-, (3R)- Preparation Products And Raw materials |
|